Corporate profile:Layout 1 14/1/10 19:59 Page 25
Corporate Profile
Faster answers in drug discovery
B
y facilitating faster and more relevant a71 Plasma protein binding
high-throughput screening, BIOCIUS a71 Permeability (Caco-2 and PAMPA)
Life Sciences helps researchers elimi- a71 CYP Induction
nate bottlenecks in the drug discovery
process. Label-free RapidFire® technology BIOCIUS’s CYP inhibition assay analysis
dramatically increases throughput of phar- service uses FDA recommended drug
maceutical screening for lead candidates and cessfully been used to screen for lead com- probes, thus mass spec analysis can now be
in vitro ADME analysis, accelerating drug pounds in an ever-expanding variety of performed early in drug discovery, eliminat-
discovery decisions and pipeline develop- therapeutic areas, including: ing the need for compromises often associ-
ment. BIOCIUS offers contract research ated with plate reader-based methods. Use
services for method development, lead dis- a71 Metabolic disease of RapidFire for in vitro ADME means that
covery and in vitro ADME as well as a71 Cardiovascular disease the same assay methods applied in
RapidFire instrumentation for use in our a71 Anti-infectives Development can now be efficiently utilised
clients’ laboratories. Supported by an expe- a71 Anti-fungals in Discovery, providing assay consistency
rienced team of scientists and engineers, a71 Central nervous system disorders throughout the drug development process.
RapidFire technology has enabled our col- a71 Oncology
laborators to make faster, more informed a71 Inflammatory disease Proven technology, trusted partner
decisions and streamline their workflows. a71 Epigenetic targets Used by 13 of the top 15 pharmaceutical
companies, RapidFire products and con-
Turning mass spectrometers Faster ADME data, no compromises tract research services have been helping
into plate readers The RapidFire system is capable of analysing our clients in pharmaceutical and biotech-
RapidFire technology incorporates serial, most in vitro ADME assays without modifi- nology companies achieve their goals since
on-line SPE directly with the mass spec- cation to existing methods or workflows. the first product launch in 2004. Our team
trometer processing at a speed of six to Multiple MS analysis methods can be run of experienced PhD scientists and engineers
eight seconds per sample from 96 or 384- with a single set-up and unattended 24-hour have screened millions of wells and taken
well plates. The technology requires no operation is possible. Data from a variety of numerous targets from assay development
labels or surrogates, enabling the investiga- in vitro ADME assays show that results from through lead discovery in support of our
tion of native molecules. Integrating easily the RapidFire system are comparable to clients’ drug discovery programmes.
with leading manufacturers’ mass spec- those from traditional LC-MS systems. Use Formed when the entire RapidFire business
trometers and standards LIMS, RapidFire of RapidFire increases the efficiency of in unit spun out of BioTrove Inc in December
instrumentation significantly increases data vitro ADME drug discovery providing high 2009, BIOCIUS Life Sciences maintains an
collection and analysis capabilities within quality data in a fraction of the time required extensive list of partners and collaborators.
existing workflows. for conventional techniques. RapidFire has
been used successfully for a wide range of Enhance productivity
Analyse even the most difficult ADME applications, including: BIOCIUS’ contract research services enable
targets laboratories to maximise their resources by
In the highly competitive drug discovery a71 CYP Inhibition outsourcing assay development, lead dis-
field, the time to identification of lead com- a71 Metabolic Stability covery and in vitro ADME screening, free-
pounds is critical. Many current therapeu- a71 P-glycoprotein inhibition ing up valuable laboratory personnel and
tic area targets are challenging to investi- equipment for other tasks. BIOCIUS’s con-
gate with traditional fluorescent or lumi- tract research service fits seamlessly into
nescent assays and the alternative of HPLC your laboratory workflow – no laborious
is too slow for processing the large sample sample preparation is required – simply
volumes required for screening pro- send BIOCIUS quenched 96 or 384-well
grammes. The RapidFire technology assay plates. RapidFire data is delivered in a
enables researchers to process these format that is easy to interpret and analyse.
intractable analytes – such as lipids, fatty To learn more about RapidFire instru-
acids, steroids and prostaglandins – with ments or contract research services from
truly label-free mass spectrometry detec- BIOCIUS, please go to our website,
tion at speeds greater than 10x faster than
www.biocius.com or visit us at booth 368
traditional HPLC-MS. RapidFire has suc- at the LabAutomation Exhibition.
Drug Discovery World Winter 2009/10 25
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88